经验性抗感染治疗.ppt

,Click to edit Master title style,Click to edit Master text styles,Second Level,Third Level,Fourth Level,Fifth Level,文档仅供参考，不能作为科学依据，请勿模仿；如有不当之处，请联系网站或本人删除。,抗感染药物发展简史,1929 Alexander Fleming,发现青霉素,Howard,Florey,和,Ernst Chain,分离获得青霉素，用于动物试验。,青霉素首次用于救治战伤患者，拯救了 许多人的生命,1950s,大量抗生素用于临床。,A poster from World War II,dramatically showing the virtues of the new miracle drug,and representing the high level of motivation in the country to aid the health of the soldiers at war.,Discovery of Antibacterial Agents,Cycloserine,Erythromycin,Ethionamide,Isoniazid,Metronidazole,Pyrazinamide,Rifamycin,Trimethoprim,Vancomycin,Virginiamycin,Imipenem,1930,1940,1950,1960,1970,1980,1990,2000,Penicillin,Prontosil,Cephalosporin C,Ethambutol,Fusidic acid,Mupirocin,Nalidixic acid,Oxazolidinones,Cecropin,Fluoroquinolones,Newer aminoglycosides,Semi-synthetic penicillins&cephalosporins,Newer carbapenems,Trinems,Synthetic approaches,Empiric,screening,Newer macrolides&ketolides,Rifampicin,Rifapentine,Semi-synthetic glycopeptides,Semi-synthetic streptogramins,Neomycin,Polymixin,Streptomycin,Thiacetazone,Chlortetracycline,Glycylcyclines,Minocycline,Chloramphenicol,“,Close the book on infectious disease”,“,Infectious disease will be with us for,the foreseeable future”,US Surgeon General,William Stewart,1969,Harvard Medical School,Mary Wilson,1998,抗生素时代感染仍是人类健康的重要威胁,IIIIIIII,新出现或“再出现”的感染性疾病,emerging and re-emerging infectious diseases,新病原体不断出现,-HIV/AIDS,、,Ebola,、,Hantavirus,新型肝炎、新型克雅病（疯牛病）肠杆菌,O157,、霍乱,O139,环孢子菌病、隐孢子菌病、人类,Ehrlichosis,老病卷土重来,-,肺结核、,疟疾、鼠疫、霍乱、黄热病、登革热,和登革出血热,免疫缺陷人群不断增加,-,机会性真菌和呼吸道病毒性肺炎,细菌耐药愈演愈烈,PRSP,、,MRSP,、,MRSA/MRSE,、,VRE,、,VISA/VERA,ESBL,、,ampC,、,SSBL,、金属酶,.,MDR,结核菌,美国因细菌耐药增加医疗费用超过,40,亿美元,!,临床关注的耐药问题,Resistances of Clinical Concerns,革兰阳性细菌,金匍菌,MRSA,VISA,VRSA,VRE,(,地理上差别,),肺炎链球菌,青霉素和喹诺酮耐药,革兰阴性细菌,肠杆菌科,ESBLs,喹诺酮,头孢菌素,青霉素类,氨基糖苷类,碳青霉烯类,非发酵菌,(,假单孢菌,+/-,不动杆菌,),喹诺酮,头孢菌素,青霉素类,氨基糖苷类,碳青霉烯类,Resistant bacteria,Mutations,XX,Antibiotic resistance:genetic events,Susceptible bacteria,Resistant bacteria,Gene transfer,Resistant StrainsRare,x,x,Resistant Strains,Dominant,Antimicrobial,Exposure,x,x,x,x,x,x,x,x,x,x,Selection for Antimicrobial-Resistant Strains,抗生素选择压力,耐药菌的播散,寻找新的抗感染药物,-,新药越来越少,限制人以外(畜牧业)使用,-,减少对人类的影响,加强抗感染药物的临床管理,-,分级和分线,合理使用抗感染药物,加强医院感染的控制,-,减少耐药菌株院内传播,细菌耐药的临床对策,-,Measures to Resistance,减少抗生素选择性压力,抗感染药物的临床应用,治疗性应用经验治疗,：,因无法确定感染的微生物，推断可能的病原体，参考本地区药敏,监,测结果，故抗生素必须覆盖所有可能的微生物，常选用联合治疗或单一广谱抗生素,治疗性应用目标治疗,：,确定了病原体，选用窄谱、低毒性的抗生素,预防性应用,：,Fighting infection in the first hours,Rapid tests,When available.Gram stain!,Start adequate antibiotic coverage,(within 1 hour?),Tillou A et al.Am Surg 2004;70:841-4,Drain purulent collection,Sampling,Including invasive procedures,when needed(BAL),经验性治疗和目标治疗的统一,留取标本进行微生物学检查,开始经验性抗感染治疗,目标治疗,Factors Selected by Multivariate Analysis Independently Related to Mortality,Variable,Relative O.R.,p Value,Underlying disease(UF+RF),3.09,.0007,Shock,2.85,0.016,Bacteremia,2.63,0.019,Ineffective Initial Therapy,4.71,.0001,Leroy O,Intensive Care Med,1995;21:24-31,Importance of Adequate and Appropriate Antimicrobial Treatment,Adequate antimicrobial treatment,Mortality,Increased,Decreased,Inadequate antimicrobial treatment,Ongoing bacterial proliferation and inflammation,selection of drug-resistant microorganisms,Ewig et al,Thorax 2002;57:366,Effect of Early Administration of Antibiotics on Outcomes,Houck PM et al.,Arch Intern Med,2004;164:637-44,Variable,All patients,Antibiotics within 4 hours,Antibiotics after 4 hours,Adjusted Odds Ratio,p Value,30-day mortality,12.0,11.6,12.7,0.85,.005,In-hospital mortality,7.0,6.8,7.4,0.85,.03,%of patients with LOS5 d,43.3,42.1,45.1,0.90,.003,30-day readm rate,13.4,13.1,13.9,0.95,.34,Early Administration of,Abx,significantly decrease mortality and LOS,Start empirical antibiotic therapy as soon as possible,慢性咳嗽和黄痰-原因,哮喘,后鼻腔鼻漏,病毒感染后气道高反应性,胃酸返流,吸烟相关的慢性支气管炎,支气管扩张症,弥漫性泛细支气管炎,肺泡蛋白沉积症,急性发热,WBC,不高,/,淋巴增高（无感染灶）病毒！,WBC,增高,/,中性粒增高,/,核左移 可能细菌！,部位,/,病原体？,原发性菌血症？,慢性发热,IE,、布病、慢性感染灶？结核病？,非感染性发热,药物热、风湿病、恶性肿瘤,正确诊断是正确治疗的前提,发热的诊断与鉴别诊断,C,ryptogenic Organizing,P,neumonia,Infectious Diseases Expert Resources,Infectious Diseases,Specialists,Optimal,Patient Care,Infection Control,Professionals,Healthcare,Epidemiologists,ClinicalPharmacists,Clinical,Pharmacologists,Surgical Infection,Experts,Clinical,Microbiologists,选择哪种抗菌药物,(which antibiotic?),感染部位的常见病原学,(possible pathogens on site of infection),选择能够覆盖病原体的抗感染药物,(antibiotics requirement),-,抗菌谱,/,组织穿透性,/,耐药性,/,安全性,/,费用,考虑药代动力学/药效动力学,(PK/PD),考虑病人生理和病理生理状态,(physiologic and pathophysiology),高龄/儿童/孕妇/哺乳,(advanced age/children/pregnant women/breast feeding),肾功能不全/肝功能不全/肝肾功能联合不全,(renal/heptic dysfunction/combined),其它因素,(other considerations),杀菌和抑菌/单药和联合/静脉和口服/疗程,(cidal vs static/mono vs combination/IV vs PO/duration),经验性抗感染治疗合理选择药物,-considerations in choosing antibiotic for empiric therapy,培养结果前依据基本信息选择抗感染药物,choosing,Abx,before culture result,感染部位和可能病原体的关系,association of pathogen with site of infection,Gram,染色结果,-,与上述病原体是否符合？,Gram stain-in accordance with suspected pathogen?,某些病原体易于造成某些部位的感染,Some pathogen easily cause some site of infection,经验性抗感染治疗药物选择,-considerations in choosing antibiotic for empiric therapy,不同感染部位的常见感染性病原体,Possible pathogens on site of infection,注意特殊修正因子,/,特别是先期抗菌药物对细菌学的影响,不同感染部位的常见感染性病原体,Possible pathogens on site of infection,关注特殊病原体,肺孢子菌肺炎,-,免疫缺陷,-,相对特异临床,-,积极病原学检查,重症军团菌肺炎,发热、少痰,多肺叶、多肺段受累,肺外表现,抗菌谱,(coverage),通读药物说明书和相关资料,组织穿透性,(tissue penetration),抗菌药物的特性,（,antibiotic itself,）,脂溶性,(lipid solubility)/,分子量,(MW),组织特性（血运/炎症）,(tissue itself-blood supply and inflammation),急性感染/慢性感染,(acute vs chronic infection),细胞内病原体,(intra vs extracellullar pathogen),体内特殊生理屏障,(physiologic barriers)-,血脑屏障、血胰屏障、胎盘屏障等,耐药性,(resistance,specifically local resistance),参考代表性资料/依靠当地资料,安全性,(safety profile),-,药物本身/制剂/工艺/杂质,费用/效益,(cost/effectiveness),失败或副作用致再治疗费用更高,经验性抗感染治疗药物选,能够覆盖可能病原体的抗菌药物（,Abx requirements,）,血脑屏障：,多数抗菌药物脑脊液浓度很低,脂溶性溶性较高、非极性、蛋白结合率低者易通过血脑屏障,炎症时血脑屏障通透性可增加,体内特殊生理屏障,胎盘屏障,：,几乎所有抗菌药物都能穿透胎盘屏障进入胚胎循环,在妊娠期应避免使用对胎儿发育有影响的抗菌药物,氯霉素、氨基糖苷类、四环素类、磺胺类、氟喹诺酮类、利福平等,抗菌药物在脑脊液中分布,氯霉素,青霉素,万古霉素,链霉素,两性霉素,B,磺胺药,氨苄西林,阿米卡星,庆大霉素,林可霉素,吡嗪酰胺,羧苄西林,奈替米星,妥布霉素,多粘菌素,B,异烟肼,哌拉西林,头孢孟多,红霉素,克林霉素,利福平,头孢噻肟,头孢哌酮,苯唑西林,乙胺丁醇,头孢他啶,甲硝唑,头孢呋新,美洛西林,环丙沙星,拉氧头孢,磷霉素,阿昔洛韦,亚胺培能,阿糖腺苷,脑膜炎症或无炎症时,csf,浓度均可达到抑菌水平（,MIC),仅在脑膜炎症时,csf,浓度均可达到抑菌水平（,MIC）,脑膜炎症时,csf,可达一定浓度,脑膜炎症时,csf,浓度仍呈微量者（60 years,2.65,Diabetes,2.57,Colodner,et al EJCMID,2004,23,163.,Prevalence of rectal carriage of Extended-Spectrum-lactamase-producing Escherichia Coli among elderly people in a community setting in Shenyang,横断面研究,/,整群抽样,-276,名社区老人、直肠拭子,/,大肠杆菌,ESBL,检测、分子分型和,PEGF,结果,:,直肠拭子,ESBL,+,大肠杆菌携带率,7.0%,（,19/270,）,.,19,株,ESBL,+,菌株,ESBL,基因型均为,CTX-M,型,12,株为,CTX-M-14,型,（,63.2%),3,株,CTX-M-22,型,1,株,CTX-M-24,型，,2,株,CTX-M-57-like,型，,1,株同时产,CTX-M-24,和,CTX-M-57-like,型,.,序列分析表明,CTX-M-57-like,基因序列中第,865,位点发生,GA,替换,导致,氨基酸序列中第,289,位点发生,DN,替换,该基因序列不同于,GenBank,数,据库已发表序列，提示新型,ESBLs,基因型,(,GenBank,序列号,EF426798),Tian SF,Chen BY.Prevalence of rectal carriage of Extended-Spectrum-lactamase-producing Escherichia Coli among elderly people in a community setting in Shenyang,China.Canadian Journal of microbiology 2008;54:15,19,株产,ESBLs,的大肠埃希菌的,PFGE,图谱,左起依次为：,Marker,，菌株编号,T2-S28.,产,ESBLs,菌株,PFGE,图谱呈多样性，,提示社区产,ESBLs,的大肠埃希菌为多克隆起源,Univariate analysis of risk factors for carriage of ESBL-producing,Escherichia coli,in the community(n=270),Potential Risk factors No(%)ESBLs Total No Odds ratio(95%CI)P value,Age(years),74 16(7.4)216,75 3(5.6)54 0.74(0.21-2.62)0.77,Gender,Female 12(7.8)153,Male 7(6.0)117 0.81(0.31-2.13)0.81,Diabetes,No 11(6.3)174,Yes 8(8.3)96 1.35(0.52-3.47)0.62,Hospitalization in past one year,No 18(6.8)264,Yes 1(16.7)6 2.73(0.30-24.66)0.34,Surgery in past one year,No 19(7.1)268,Yes 0(0)2 0.0 0.8,Use of antibiotic in past three months,No 12(5.3)227,Yes 7(16.3)43 3.48(1.29-9.44).018,产,ESBL,细菌感染的危险因素,Prospective study of 455 episodes of K.pneumoniae bacteremia(253 nosocomial)in 12 hospitals,30.8%,为医院获得,ICU,中,43.5%,产,ESBLs,ESBLs,危险因素,先期使用氧亚氨基,-,内酰胺类抗菌药物,过去,14,天内使用,2 d(OR=3.9).,其它危险因素,TPN,肾功衰竭,烧伤,非,ESBL,危险,:,碳青霉烯、头孢吡肟、喹诺酮、氨基糖苷类,Paterson et al:Ann Intern Med 2004;140:26-32.,VAP,耐药菌感染的危险因素,135,次,VAP,ICU,变量,OR,P,MV7 days,6,.0,.009,先期,ABs,13,.5,7 days,/,prior ABs,Trouillet,et al.,Am J Respir Crit Care Med.,1998;157:531,Trouillet JL et al.,Clin Infect Dis,.2002;34:1047-1054.,铜绿,VAP:34,株派拉西林耐药,;101,株派拉西林敏感,发生,VAP15,天内使用抗菌药（亚胺培南,3,代头孢和喹诺酮,),增加铜绿对同种药物的耐药性,a,P,=.0009,b,P,=.003,c,P,=.001,d,P,=.05,Resistance of,P aeruginosa,Strains To Imipenem,Ceftazidime,or Ciprofloxacin,According to Previous Therapy With Imipenem,a 3rd-generation Cephalosporin,or a Fluoroquinolone,No.(%)of patients,by previous drug therapy received,Imipenem,Third-generation cephalosporin,Fluoroquinolone,Strain resistance,No,(n=114),Yes,(n=21),No,(n=73),Yes,(n=62),No,(n=100),Yes,(n=35),To imipenem,19(16.7),11(52.4),a,12(16.4),18(29.0),18(18),12(34.3),d,To ceftazidime,17(14.9),7(33.3),6(8.2),18(29.0),b,14(14),10(28.6),To ciprofloxacin,35(30.7),11(52.4),25(34.2),21(33.9),26(26),20(57.1),c,关注耐药病原体,-,近期应用抗菌药物与铜绿耐药,S.aureus,Penicillin,1944,Penicillin-resistant,S.aureus,金黄色葡萄球菌耐药的发生发展过程,Methicillin,1962,Methicillin-resistant,S.aureus,(MRSA),Vancomycin-resistant,enterococci(VRE),Vancomycin,1990,s,1997,Vancomycin,intermediate,S.aureus,(VISA),2002,Vancomycin-,resistant,S.aureus,CDC,MMWR,2002;51(26):565-567,1960,Macrolide resistant S.pneumoniae in Asian Countries:ANSORP 1998-2001,-555 isolates,-macrolide susceptibility,-216 S(38.9%),-10 I (1.8%),-329 R(59.3%),Vietnam88.3%RHong Kong 76.5%R,Taiwan87.2%RChina75.6%R,Korea85.1%R,-,ermB,more common(50%)China,Taiwan,Sri Lanka,Korea.,-,mefA,more common Hong Kong,Singapore,Thailand,Malaysia.,-most countries MIC,90,12 mg/L.,Song,et al,Journal of Antimicrobial Chemotherapy 2004;53(3):457-463.,红霉素耐药肺炎链球菌表型和基因型,赵铁梅，刘又宁.中华内科杂志.2004,;,43,(5),:329-332/,AAC,2004;48（10）:,4040-4041,耐药表型,基因型,N=148,抗菌谱,(coverage),通读药物说明书和相关资料,组织穿透性,(tissue penetration),抗菌药物的特性,（,antibiotic itself,）,脂溶性,(lipid solubility)/,分子量,(MW),组织特性（血运/炎症）,(tissue itself-blood supply and inflammation),急性感染/慢性感染,(acute vs chronic infection),细胞内病原体,(intra vs extracellullar pathogen),体内特殊生理屏障,(physiologic barriers)-,血脑屏障、血胰屏障、胎盘屏障等,耐药性,(resistance,specifically local resistance),参考代表性资料/依靠当地资料,安全性,(safety profile),-,药物本身/制剂/工艺/杂质,费用/效益,(cost/effectiveness),失败或副作用致再治疗费用更高,经验性抗感染治疗药物选,能够覆盖可能病原体的抗菌药物（,Abx requirements,）,评估责任病原体,评估病原体耐药性,Avoiding the adverse outcomes of resistanceindividual patient perspective,应用耐药可能性低的药物到位！,治疗决定个体化,耐药的可能性？,病人的致病微生物？,病人来源,?,选择压力,用当地的监测资料不越位！,耐药,交叉耐药资料,选择哪种抗菌药物,(which antibiotic?),感染部位的常见病原学,(possible pathogens on site of infection),能够覆盖病原体的抗感染药物,(,antibiotics requirement),抗菌谱,coverage)/,组织穿透性,(tissue penetration)/,耐药性,(resistance pattern)/,安全性,(safety)/,费用,(cost),优化药代动力学/药效动力学,(optimizing PK/PD),考虑病人生理和病理生理状态,(,physiologic and pathophysiology),高龄/儿童/孕妇/哺乳,(,advanced age/children/pregnant women/breast feeding),肾功能不全/肝功能不全/肝肾功能联合不全,(,renal/heptic dysfunction/combined),其它因素,(,other considerations),杀菌和抑菌/单药和联合/静脉和口服/疗程,合理的经验性抗感染治疗药物选择,considerations in choosing antibiotic for empiric therapy,Pharmacology of Antimicrobial Therapy,Dosing,regimen,Concentrations,in serum,Concentrationsin tissues and body fluids,Concentrationsat site of infection,Pharmacologic and toxicologic effect,Antimicrobialeffect,AbsorptionDistributionElimination,Pharmacokinetics,(PK),Pharmacodynamics,(PD),MIC,、,MBC,Different pattern of time-killing of 3 Abx,VS,Pseudomonas,Killing and rate of killing depends on concentration,Rate of killing increases no more as concentration increases,killing depends on exposure time,PK/PD Predictors of Efficacy,-a combination of PK and PD,Time,MIC,90,Log Concentration,24h-AUC,T MIC,C,max,C,max,/MIC,24h-AUC/MIC,(,AUIC,),Dose,Dose,Cmax,TMIC,Parameters of interest,PK/PD Predictors of Efficacy,依据,PK/PD,抗菌药物分类,时间依赖性,与时间有关，但抗菌活性持续时间较长,对致病菌的杀菌作用,取决于峰浓度,抗菌作用与,同细菌接触时间密切相关,时间依赖且,PAE,或,T1/2,较长,氨基糖苷类、氟喹诺酮类、,酮内酯类、两性霉素,B、,daptomycin、,甲硝唑,多数,-,内酰胺类、,林可霉素类,恶唑烷酮类、氟胞嘧啶,链阳霉素、四环素、,碳青霉烯类、糖肽类、,大环内酯类、唑类抗真菌药,主要参数,AUC,0-24,/MIC(AUIC),C,max,/MIC,主要参数,T,MIC,和,AUC,MIC,主要参数,T,MIC,PAE，T1/2,AUC/MIC,浓度依赖性,Required%TMIC for cidal:,40%for carbapenems,50%for penicillins,70%for cephalosporins,Drusano GL.,Clin Infect Dis.,2003;36(suppl 1):S42-S50.,R,equired%TMIC for static,20%,for carbapenems,30%,for penicillins,40%,for cephalosporins,-,lactam,:,optimal TMIC?,Drusano.Clin Infect Dis 2003;36(Suppl.1):S42S50,Maximizing TMIC,提高剂量安全性前体,增加给药频率,延长输注时间,-,内酰胺类优化暴露时间,-Lactam:Optimizing Exposure,Dandekar PK et al.,Pharmacotherapy.,2003;23:988-991.,Meropenem 500 mg Administered as a 0.5 h or 3 h Infusion,MIC,0,2,4,6,8,0.1,1.0,10.0,100.0,Concentration(mcg/mL),Time(h),Rapid Infusion(30 min),Extended Infusion(3 h),Treatment of Multidrug-resistant B,urkholderia cepacia,With Prolonged Infusion Meropenem,Meropenem 2 g infused over 3 hours q 8 h,Time(h),Concentration,(mcg/mL),0,8,16,24,32,40,0.1,1,10,100,MIC=16 mcg/mL,TMIC exposure was 40%of the dosing interval at the MIC of16 mcg/mL,Kuti JL et al.,Pharmacotherapy.,2004;24:1641-1645,Moore et al.J Infect Dis 1987;155:9399,Aminoglycoside:optimal,C,max,:MIC,-Relationship Between C,max,:MIC and Clinical Response,Clinical response(%),C,max,:MIC,0,20,40,60,80,100,2,4,6,8,10,12,55,65,70,83,89,92,What is the Optimal AUIC for Fluoroquinolones?,30,125,For G,+,For G,-,Forrest et al.Antimicrob Agents Chemother 1993;37:10731081,Fluoroquinolone Therapy for Nosocomial Pneumonia,Correlation Between Drug Exposure(AUC/MIC)&Outcome,Patients cured(%),0,20,40,60,80,100,062.5,62.5125,125250,250500,500,AUC:MIC,Clinical,Microbiological,AUC:MIC125,lead to appropriate clinical and microbiological outcome,Gram-Negative Bacterial Eradication,and Fluoroquinolone AUIC,Days,0 2,4 6,8 10 12 14,0,100,75,50,25,AUIC 125-250,AUIC 250,AUIC 125,%Patients remaining culture positive,Forrest et al.,Antimicrob Agents Chemother,.1993;37:1073-1081,Higher AUC:MIC,lead to letter bacterial eradication,Probability of Developing Resistance,Thomas KL et al.,Antimicrob Agents Chemother,.1998;42:521527,AUC,024h,:MIC,100,AUC,024h,:MIC 100,Free AUIC 30-40,Resistance prevention,C,max,MPC,Higher,AUIC,Baquero 19:731-6,Drlica K.ASM News 2001;67:27-33,Cantn et al.Inter J Antimicrob Chemother 2006(in press),Concentration (g/ml),Time post,administration(h),Cmax,MPC,Tmax,MIC,Window,of,selection,MIC,MPC,(MIC of mutants),Resistant mutant,Susceptible bacteria,选择哪种抗菌药物,(which antibiotic?),感染部位的常见病原学,(possible pathogens on site of infection),能够覆盖病原体的抗感染药物,(,antibiotics requirement),抗菌谱,coverage)/,组织穿透性,(tissue penetration)/,耐药性,(resistance pattern)/,安全性,(safety)/,费用,(cost),优化药代动力学/药效动力学,(optimizing PK/PD),考虑病人生理和病理生理状态,(,physiologic and pathophysiology),高龄/儿童/孕妇/哺乳,(,advanced age/children/pregnant women/breast feeding),肾功能不全/肝功能不全/肝肾功能联合不全,(,renal/heptic dysfunction/combined),其它因素,(,other considerations),杀菌和抑菌/单药和联合/静脉和口服/疗程,合理的经验性抗感染治疗药物选择,considerations in choosing antibiotic for empiric therapy,老人感染特点,易发生细菌感染,常见肺炎、尿感、胆道感染、败血症,常见菌,:G-,杆、金葡、肺球、肠球、真菌,老人抗菌药药理,肾功减退，半减期长，血浓度高,肝解毒功能降低,组织退化、防御功能低，胃、尿、胆汁中常有菌,水量减少，药物在脂肪中浓度高,白蛋白减少，游离药物多,老人抗菌治疗,宜用杀菌剂,避免肾毒性药物,有条件的做,TDM(,特别用肾毒性药物时,),不良反应多，且不易发现,肝肾清除减退剂量宜低